Our research is focused on the screening of different phenotypes of malignant melanoma by RCM for the expression and activity of TPC2 lysosomal channel and this information will be highly informative both for patients’ stratification and for disclosing a novel possible therapeutic target. We aim to identify the activity of TPC2 in different malignant melanoma subtypes, as selected by RCM. Furthermore, the clinical and biomolecular data will allow us to predict the specific metastatic potential/stage, at the same time revealing a new possible druggable target to be used for a tailored therapy for malignant melanoma patients. The most important goal of this study is to contribute to the development of theranostics, the new strategies that combine non-invasive imaging-based diagnostics with therapy to bypass tumour drug resistance.
